Search research articles
Contact Us
Filters
Showing results (171-180 of 177) with videos related to
Page
of 18
Sort By:
You have reached the last page of results.
This site can display upto 177 results.
ACS Medicinal Chemistry Letters
|
December 21, 2016
Sulfonamides as Selective Na<sub>V</sub>1.7 Inhibitors: Optimizing Potency and Pharmacokinetics to Enable in Vivo Target Engagement
Isaac E Marx, Thomas A Dineen, Jessica Able, et al.
ACS Medicinal Chemistry Letters
|
March 25, 2017
Correction to "Sulfonamides as Selective Na<sub>V</sub>1.7 Inhibitors: Optimizing Potency and Pharmacokinetics to Enable <i>in Vivo</i> Target Engagement"
Isaac E Marx, Thomas A Dineen, Jessica Able, et al.
Bioorganic & Medicinal Chemistry Letters
|
June 21, 2017
The discovery of benzoxazine sulfonamide inhibitors of Na<sub>V</sub>1.7: Tools that bridge efficacy and target engagement
Daniel S La, Emily A Peterson, Christiane Bode, et al.
Journal of Medicinal Chemistry
|
March 14, 2017
Sulfonamides as Selective Na<sub>V</sub>1.7 Inhibitors: Optimizing Potency and Pharmacokinetics While Mitigating Metabolic Liabilities
Matthew M Weiss, Thomas A Dineen, Isaac E Marx, et al.
ACS Chemical Biology
|
March 16, 2019
Engineering Na<sub>V</sub>1.7 Inhibitory JzTx-V Peptides with a Potency and Basicity Profile Suitable for Antibody Conjugation To Enhance Pharmacokinetics
Justin K Murray, Bin Wu, Christopher M Tegley, et al.
Journal of Medicinal Chemistry
|
March 22, 2017
Sulfonamides as Selective Na<sub>V</sub>1.7 Inhibitors: Optimizing Potency, Pharmacokinetics, and Metabolic Properties to Obtain Atropisomeric Quinolinone (AM-0466) that Affords Robust in Vivo Activity
Russell F Graceffa, Alessandro A Boezio, Jessica Able, et al.
Science (New York, N.Y.)
|
November 1, 2003
Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor
Paul S Changelian, Mark E Flanagan, Douglas J Ball, et al.
Page
of 18
Search research articles
Search
Showing results (171-180 of 177) with videos related to
Sort By:
Page
of 18
You have reached the last page of results.
This site can display upto 177 results.
ACS Medicinal Chemistry Letters
|
December 21, 2016
Sulfonamides as Selective Na<sub>V</sub>1.7 Inhibitors: Optimizing Potency and Pharmacokinetics to Enable in Vivo Target Engagement
Isaac E Marx, Thomas A Dineen, Jessica Able, et al.
ACS Medicinal Chemistry Letters
|
March 25, 2017
Correction to "Sulfonamides as Selective Na<sub>V</sub>1.7 Inhibitors: Optimizing Potency and Pharmacokinetics to Enable <i>in Vivo</i> Target Engagement"
Isaac E Marx, Thomas A Dineen, Jessica Able, et al.
Bioorganic & Medicinal Chemistry Letters
|
June 21, 2017
The discovery of benzoxazine sulfonamide inhibitors of Na<sub>V</sub>1.7: Tools that bridge efficacy and target engagement
Daniel S La, Emily A Peterson, Christiane Bode, et al.
Journal of Medicinal Chemistry
|
March 14, 2017
Sulfonamides as Selective Na<sub>V</sub>1.7 Inhibitors: Optimizing Potency and Pharmacokinetics While Mitigating Metabolic Liabilities
Matthew M Weiss, Thomas A Dineen, Isaac E Marx, et al.
ACS Chemical Biology
|
March 16, 2019
Engineering Na<sub>V</sub>1.7 Inhibitory JzTx-V Peptides with a Potency and Basicity Profile Suitable for Antibody Conjugation To Enhance Pharmacokinetics
Justin K Murray, Bin Wu, Christopher M Tegley, et al.
Journal of Medicinal Chemistry
|
March 22, 2017
Sulfonamides as Selective Na<sub>V</sub>1.7 Inhibitors: Optimizing Potency, Pharmacokinetics, and Metabolic Properties to Obtain Atropisomeric Quinolinone (AM-0466) that Affords Robust in Vivo Activity
Russell F Graceffa, Alessandro A Boezio, Jessica Able, et al.
Science (New York, N.Y.)
|
November 1, 2003
Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor
Paul S Changelian, Mark E Flanagan, Douglas J Ball, et al.
Page
of 18